Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL08265/0029.
Olmetec Plus 40mg/12.5mg Film-coated Tablets
Olmetec Plus 40 mg/12.5 mg
Film-coated tablets
olmesartan medoxomil/hydrochlorothiazide
1. What Olmetec Plus is and what it is used for
2. What you need to know before you take Olmetec Plus
3. How to take Olmetec Plus
4. Possible side effects
5. How to store Olmetec Plus
6. Contents of the pack and other information
Olmetec Plus contains two active substances, olmesartan medoxomil and hydrochlorothiazide, that are used to treat high blood pressure (hypertension):
You will only be given Olmetec Plus if Olmetec (olmesartan medoxomil) alone has not adequately controlled your blood pressure. When given together, the two active substances in Olmetec Plus help to lower blood pressure more than if either of them were given alone.
You may already be taking medicines to treat your high blood pressure, but your doctor may want you to take Olmetec Plus to lower it more.
High blood pressure can be controlled with medicines such as Olmetec Plus tablets. Your doctor has probably also recommended that you make some changes in your lifestyle to help lower your blood pressure (for example losing weight, giving up smoking, reducing the amount of alcohol you drink and reducing the amount of salt in your diet). Your doctor may also have urged you to take regular exercise, such as walking or swimming. It is important to follow this advice from your doctor.
If you think any of these apply to you, or you are unsure, do not take the tablets. Talk to your doctor first and follow the advice given.
Talk to your doctor before using Olmetec Plus.
Before you take the tablets, tell your doctor if you are taking any of the following medicines used to treat high blood pressure:
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.
See also information under the heading “Do not take Olmetec Plus”.
Before you take the tablets, tell your doctor if you have any of the following health problems:
Contact your doctor if you experience any of the following symptoms:
Your doctor may want to see you more often and do some tests if you have any of these conditions.
Olmetec Plus may cause a rise in blood fat levels and uric acid levels (the cause of gout – painful swelling of the joints). Your doctor will probably want to do a blood test from time to time to check these.
It may change the levels of certain chemicals in your blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check these. Signs of electrolyte changes are: thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass urine, a rapid heart rate. Tell your doctor if you notice these symptoms.
As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.
If you are due to have tests for parathyroid function, you should stop taking Olmetec Plus before these tests are carried out.
If you are a sports person, this medicine could change the results of an anti-dope test to make it positive.
You must tell your doctor if you think that you are (or might become) pregnant. Olmetec Plus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Olmetec Plus is not recommended for children and adolescents under the age of 18.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
In particular, tell your doctor or pharmacist about any of the following:
Olmetec Plus can be taken with or without food.
Take care when drinking alcohol while you are taking Olmetec Plus, as some people feel faint or dizzy. If this happens to you, do not drink any alcohol, including wine, beer or alcopops.
As with other similar drugs the blood pressure lowering effect of Olmetec Plus is somewhat less in black patients.
Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Olmetec Plus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Olmetec Plus. Olmetec Plus is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Olmetec Plus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You may feel sleepy or dizzy while being treated for your high blood pressure. If this happens, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.
This medicine contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one Olmetec Plus 40 mg/12.5 mg tablet a day. However, if your blood pressure is not controlled, your doctor may decide to change your dose to one Olmetec Plus 40 mg/25 mg tablet a day.
Swallow the tablet with water. If possible, you should take your dose at the same time each day, for example at breakfast time. It is important to continue to take Olmetec Plus until your doctor tells you to stop.
If you take more tablets than you should, or if a child accidentally swallows one or more, go to your doctor or nearest accident and emergency (A&E) department immediately and take your medicine pack with you.
If you forget to take a dose, take your normal dose on the following day as usual. Do not take a double dose to make up for a forgotten dose.
It is important to continue to take Olmetec Plus unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
However, the following side effects can be serious:
Olmetec Plus is a combination of two active substances and the following information firstly gives the other side effects reported so far with the combination Olmetec Plus (besides those already mentioned above) and, secondly, those which are known about for the separate active substances.
If these side effects occur, they are often mild and you do not need to stop your treatment.
Common side effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, tiredness, chest pain, swelling of ankles, feet, legs, hands or arms.
Uncommon side effects (may affect up to 1 in 100 people):
Fluttering of the heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhoea, muscle cramps and muscular pain, pain in joints, arms and legs, back pain, erection difficulties in men, blood in urine.
Some changes in blood test results have also been seen uncommonly and include:
Rise in blood fat levels, rise in blood urea or uric acid, rise in creatinine, rise or decrease in blood potassium levels, rise in blood calcium levels, rise in blood sugar, increase in levels of liver function. Your doctor will know about these from a blood test and will tell you if you need to do anything.
Rare side effects (may affect up to 1 in 1,000 people):
Feeling unwell, disturbances in consciousness, skin lumps (wheals), acute kidney failure.
Some changes in blood test results have also been seen in rare cases and include:
Rise in blood urea nitrogen, decrease in haemoglobin and haematocrit values. Your doctor will know about these from a blood test and will tell you if you need to do anything.
Olmesartan medoxomil:
Common side effects (may affect up to 1 in 10 people):
Bronchitis, cough, runny or stuffy nose, sore throat, abdominal pain, indigestion, diarrhoea, nausea, gastroenteritis, pain in the joints or bones, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Some changes in blood test results have also been seen commonly and include:
Rise in blood fat levels, rise in blood urea or uric acid, increase in levels of liver and muscle function.
Uncommon side effects (may affect up to 1 in 100 people):
Quick allergic reactions that may affect the whole body and may cause breathing problems as well as a rapid fall of blood pressure that may even lead to fainting (anaphylactic reactions), swelling of the face, angina (pain or uncomfortable feeling in the chest; known as angina pectoris), feeling unwell, allergic skin rash, itching, exanthema (skin eruption), skin lumps (wheals).
Some changes in blood test results have also been seen uncommonly and include:
Reduced numbers of a type of blood cell, known as platelets (thrombocytopenia).
Rare side effects (may affect up to 1 in 1,000 people):
Impaired kidney function, lack of energy.
Some changes in blood test results have also been seen rarely and include:
Increase in blood potassium.
Hydrochlorothiazide:
Very common side effects (may affect more than 1 in 10 people):
Changes in blood results including: Increase in blood fat and uric acid levels.
Common side effects (may affect up to 1 in 10 people):
Feeling confused, abdominal pain, stomach upset, bloated feeling, diarrhoea, nausea, vomiting, constipation, excretion of glucose into the urine.
Some changes in blood results have also been seen and include:
Increase in blood creatinine, urea, calcium and sugar levels, decrease in blood chloride, potassium, magnesium and sodium levels. Increase of serum amylase (hyperamylasaemia).
Uncommon side effects (may affect up to 1 in 100 people):
Decreased or loss of appetite, severe difficulty breathing, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia erythema, skin reactions to light, itching, purplish spots or patches on the skin due to small haemorrhages (purpura), skin lumps (wheals).
Rare side effects (may affect up to 1 in 1,000 people):
Swollen and sore salivary glands, decreased number of white blood cells, decreased number of blood platelets, anaemia, bone marrow damage, restlessness, feeling ‘down’ or depressed, problems sleeping, feeling un-interested (apathy), tingling and numbness, fits (convulsions), objects you look at appearing yellow, blurred vision, dry eyes, irregular heartbeat, inflammation of the blood vessels, blood clots (thrombosis or embolism), inflammation of the lung, fluid accumulation in the lungs, inflammation of the pancreas, jaundice, infection in the gall bladder, symptoms of lupus erythematosus (such as rash, joint pains and cold hands and fingers), allergic skin reactions, peeling and blistering of the skin, non-infectious inflammation of the kidney (interstitial nephritis), fever, muscle weakness (sometimes causing impaired movement).
Very rare side effects (may affect up to 1 in 10,000 people):
Electrolyte disturbance leading to an abnormally depleted level of chloride in the blood (hypochloraemic alkalosis), blockage in the gut (paralytic ileus).
Acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion).
Not known (frequency cannot be estimated from the available data):
Decrease in vision or eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
Skin and lip cancer (Non-melanoma skin cancer).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicinal product does not require any special storage conditions.
Do not use this medicine after the expiry date which is stated on the carton and on the blister strip after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are:
Olmetec Plus 40 mg/12.5 mg: Each film-coated tablet contains 40 mg olmesartan medoxomil and 12.5 mg hydrochlorothiazide.
Olmetec Plus 40 mg/25 mg: Each film-coated tablet contains 40 mg olmesartan medoxomil and 25 mg hydrochlorothiazide.
The other ingredients are:
Microcrystalline cellulose, lactose monohydrate*, low substituted hyprolose, hyprolose, magnesium stearate, titanium dioxide (E 171), talc, hypromellose, iron (III) oxides (E 172).
* See ‘Olmetec Plus contains lactose’ section above
Olmetec Plus 40 mg/12.5 mg film-coated tablets of 15 x 7 mm are reddish-yellow, oval with "C23" on one side.
Olmetec Plus 40 mg/25 mg film-coated tablets of 15 x 7 mm are pinkish, oval with "C25" on one side.
They are available in packs of 14, 28, 30, 56, 84, 90, 98, 10 x 28 and 10 x 30 film-coated tablets and in packs with perforated unit dose blisters of 10, 50 and 500 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
Manufacturer:
This medicinal product is authorised in the Member States of the EEA under the following names:
Austria: Olmetec Plus
Belgium: Olmetec Plus
Denmark: Olmetec Plus
Germany: Olmetec Plus
Greece: Olmetec Plus
Finland: Olmetec Plus
France: CoOlmetec
Iceland: Olmetec Plus
Ireland: Benetor Plus
Italy: Olmegan
Luxembourg: Olmetec Plus
The Netherlands: Olmetec HCTZ
Norway: Olmetec Comp
Portugal: Olmetec Plus
Spain: Olmetec Plus
UK: Olmetec Plus
This leaflet was last revised in March 2022.
Other sources of information
Detailed information on this medicine is available on the web site of: UK/MHRA.
olmetec-plus-40-12.5-pil-uk-v14-220302